The FDA approved the first test to assess opioid addiction risk; Americans are using more cold and allergy medicines to mask any related symptoms to return to work and social gatherings, but may be overtreating themselves in the process; Rite Aid will be banned from using artificial intelligence–powered facial recognition technology for 5 years under a proposed Federal Trade Commission settlement.
Areas where fireworks were legal had slightly higher odds of firework-related ocular trauma in their residents.
Patients with non–small cell lung cancer (NSCLC) who tested positive for driver gene alteration had longer overall survival when given targeted therapy.
This year’s top 5 most-listened to podcasts included topics on digital health solutions, cardiology, value-based care initiatives, and oncology.
The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.
Increased pulmonary arterial hypertension (PAH) awareness and earlier screening in routine clinical practice could provide an opportunity for earlier treatment, resulting in reduced economic burden for payers, employers, and society at large.
A new survey from the National Alliance of Healthcare Purchaser Coalitions found that employers are planning to place a larger focus on obesity management, women’s health, and health equity in 2024 and beyond.
Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.
From the 2023 Academy of Managed Care Pharmacy (AMCP) Nexus meeting, held in October, expert interviews and insightful updates on the Inflation Reduction Act, gene therapy affordability and access, and the 340B Drug Pricing Program comprise the conference highlights.
Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Our top conference coverage of 2023 covered a range of topics, including cardiovascular disease, heart failure, breast cancer, and chronic lymphocytic leukemia.
CDC warns of rapid spread of new COVID-19 JN.1 subvariant amidst holiday travel; drugmakers and physicians experience significant drops in reputation; HHS urges action amidst soaring drop in child enrollment for Medicaid plans.
Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.
Maternal vaccination during pregnancy may provide important protection before infants are eligible to receive a vaccine, a study suggests.
These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer.
Most studies involving the treatment of psoriasis do not contain any images of patients, a review finds.
The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old.
This year’s most-read asthma articles included the impact of extreme weather events, neighborhood determinants of health, and other risk factors for asthma exacerbations.
Patients aged 80 years and older with colorectal cancer (CRC) could have an improved prognosis at the completion of adjuvant chemotherapy.
This year’s most-read articles on inflammation explored predictive biomarkers, medication acceptance, the impacts of long COVID-19, and more.
Posters presented at the American Society of Hematology Annual Meeting and Exposition identified factors associated with reducing risk and improving survival in patients with polycythemia vera (PV).
The researchers explained that future studies should explore how the physical, emotional, and social impact of hepatitis B on patients could be measured and incorporated into clinical management.
Patients who had concurrent thrombotic thrombocytopenic purpura (TTP) and COVID-19 had elevated risk of mortality and other complications.
In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.
Initiative aims to enhance maternal health and birth outcomes; Wegovy success will help fund a vaccines initiative for respiratory diseases; new tactics aim to remove abortion from the 2024 ballot
The top 5 most-read news content for 2023 featured COVID-19 vaccination uptake and its relation to HIV viral suppression, those more likely to get vitamin D supplements, and recurrence of Clostridioides difficile infection.
In 2023, adalimumab biosimilars took center stage in the biosimilar space due to 8 long-anticipated products finally launching.
David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure, shared that the organization is able to reduce clinical trial costs to $1 to $5 million per drug trial, and that clinical trials are not always necessary to expand a drug's indication.
In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.
